SION

+ Watchlist + Portfolio

Sionna Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $6.25
52-Week Range: $4.01 – $54.97
Market Cap: $249.23M
P/E (TTM): —
EPS (TTM): -1.90
Dividend Yield: —

Advanced Metrics

Price/Book: 0.94
PEG Ratio: —
Return on Equity: -32.34%
Return on Assets: -21.54%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 20.05
Debt/Equity: 0.03
Total Debt: $8.07M
Free Cash Flow: $-45.44M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $46.61M

SION Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$34.60M	$40.63M	$57.29M	$60.26M
Selling, General & Admin	$6.77M	$9.71M	$13.27M	$28.72M
Operating Expenses	$41.37M	$50.33M	$70.56M	$88.98M
Operating Income	-$41.37M	-$50.33M	-$70.56M	-$88.98M
EBITDA	-$41.25M	-$49.75M	-$69.89M	-$88.33M
Pretax Income	-$40.24M	-$47.26M	-$61.69M	-$75.27M
Net Income	-$40.24M	-$47.26M	-$61.69M	-$75.27M
Diluted EPS	-2.32	-1.70	-1.45	-1.88
Diluted Shares	17.33M	27.80M	42.44M	39.96M

SION Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$54.84M	$38.52M	$37.79M	$58.45M
Current Assets	$83.83M	$39.21M	$150.99M	$241.42M
Total Assets	$87.37M	$51.95M	$185.75M	$325.95M
Current Liabilities	$8.25M	$8.04M	$10.42M	$11.71M
Total Debt	$0.00	$10.48M	$9.75M	$8.68M
Total Liabilities	$157.29M	$166.83M	$349.46M	$19.12M
Retained Earnings	-$72.14M	-$119.40M	-$181.09M	-$256.35M
Shareholders' Equity	-$69.92M	-$114.88M	-$163.71M	$306.83M
Working Capital	$75.58M	$31.17M	$140.57M	$229.71M

SION Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$36.07M	-$43.70M	-$52.79M	-$66.30M
Capital Expenditure	-$1.87M	-$1.12M	-$27.00K	-$377.00K
Free Cash Flow	-$37.94M	-$44.81M	-$52.81M	-$66.67M
Depreciation & Amortisation	$122.00K	$583.00K	$668.00K	$647.00K
Stock-Based Compensation	$1.69M	$2.26M	$3.71M	$12.07M
Investing Cash Flow	-$29.26M	$27.35M	-$126.91M	-$118.75M
Financing Cash Flow	$110.86M	$31.00K	$178.97M	$205.71M
Net Change in Cash	$45.52M	-$16.32M	-$733.00K	$20.66M

SION Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$13.67M	$15.38M	$16.04M	$15.17M	$18.96M
Selling, General & Admin	$5.56M	$6.04M	$7.24M	$9.87M	$10.15M
Operating Expenses	$19.66M	$21.91M	$23.80M	$23.61M	$29.60M
Operating Income	-$19.66M	-$21.91M	-$23.80M	-$23.61M	-$29.60M
EBITDA	-$19.23M	-$21.43M	-$23.29M	-$23.46M	-$29.11M
Pretax Income	-$16.48M	-$18.07M	-$20.28M	-$20.44M	-$26.78M
Net Income	-$16.48M	-$18.07M	-$20.28M	-$20.44M	-$26.78M
Diluted EPS	-0.62	-0.41	-0.46	-0.46	-0.60
Diluted Shares	26.60M	44.12M	44.26M	44.64M	44.92M

SION Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$82.69M	$40.98M	$50.83M	$58.45M	$63.32M
Current Assets	$273.68M	$266.75M	$252.33M	$241.42M	$220.96M
Total Assets	$369.67M	$352.05M	$339.27M	$325.95M	$305.04M
Current Liabilities	$9.53M	$7.55M	$9.85M	$11.71M	$9.78M
Total Debt	$9.50M	$9.24M	$8.97M	$8.68M	$8.38M
Total Liabilities	$17.91M	$15.62M	$17.60M	$19.12M	$16.83M
Retained Earnings	-$197.57M	-$215.64M	-$235.91M	-$256.35M	-$283.13M
Shareholders' Equity	$351.77M	$336.43M	$321.67M	$306.83M	$288.21M
Working Capital	$264.15M	$259.20M	$242.48M	$229.71M	$211.18M

SION Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$16.29M	-$18.15M	-$15.23M	-$16.63M	-$21.84M
Capital Expenditure	-$86.00K	—	-$87.00K	-$204.00K	—
Free Cash Flow	-$16.37M	-$18.15M	-$15.32M	-$16.83M	-$21.84M
Depreciation & Amortisation	$159.00K	$147.00K	$189.00K	$152.00K	$154.00K
Stock-Based Compensation	$2.09M	$2.84M	$3.31M	$3.83M	$6.55M
Investing Cash Flow	-$141.19M	-$23.25M	$23.10M	$22.59M	$24.82M
Financing Cash Flow	$202.39M	-$312.00K	$1.97M	$1.66M	$1.89M
Net Change in Cash	$44.91M	-$41.71M	$9.85M	$7.62M	$4.87M

Market Snapshot

About

Sionna Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for inflammatory and fibrotic diseases. The company utilizes its proprietary TRADE platform to discover and develop small molecule therapeutics targeting critical disease pathways.